Quotables
"Inventing is a combination of brains and materials. The more brains you use, the less material you need."
Charles Kettering
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128738 | Theobromine for the Treatment of Cough The present invention is theobromine as an active agent to be delivered via the inhaled route, for the treatment of cough.... | 05/24/2012 |
| 20120128777 | COMPOSITIONS CONTAINING LIPID MICRO- OR NANOPARTICLES FOR THE ENHANCEMENT OF THE DERMAL ACTION OF SOLID PARTICLES The invention is related to compositions which can be used as dermal formulations for supporting the skin to restore normal conditions in case of e.g. irritated skin, or to support medical therapy of skin with atopic dermatitis symptoms, atopic dermatitis, psoriasis or ... | 05/24/2012 |
| 20120039818 | ANTI-CHAFING AEROSOL POWDER A composition and method which prevents or mitigates irritation on the skin of a subject by protecting against or relieving chafing, itching and moisture, and which provides a cooling sensation where applied.... | 02/16/2012 |
| 20110293680 | Composition of a Temporary Hair Thickener The present invention relates to a composition of a temporary hair thickener. In particular, the present invention relates to a composition of a temporary hair thickener comprising bamboo charcoal powder, a hydrophobic waterproof coating agent, a low grade alcohol and a... | 12/01/2011 |
| 20110262502 | PULMONARY DELIVERY OF 17-HYDROXYPROGESTERONE CAPROATE (17-HPC) The invention relates to 17-HPC pulmonary formulations for administration by inhalation comprising 17-HPC and a pharmaceutically acceptable excipient. Particle size reduction of 17-HPC is required for the pulmonary delivery, and can be achieved with a surfactant or wate... | 10/27/2011 |
| 20110206771 | Encapsulated functional fine particle composition capable of spraying and preparation method thereof Provided is an encapsulated functional fine particle composition capable of spraying that is useful for hemostasis and wound protection and allows a patient to treat the wound by oneself. Additionally, the composition can be rapidly applied on a large wound during an op... | 08/25/2011 |
| 20110097281 | FOAM SKIN CARE CREAM The present invention relates to a formulation comprising an aqueous emulsion and a blowing agent for a foaming skin cream, a distinctive feature thereof being that the emulsion comprises microsilver.... | 04/28/2011 |
| 20110097282 | New Use For Budesonide and Formoterol The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.... | 04/28/2011 |
| 20110038807 | COMPOSITIONS AND METHODS FOR TREATING BIPOLAR DISORDER The present invention is directed to a method for treating bipolar disorder, childhood-onset bipolar disorder, and associated symptoms. The method includes administering to a subject in need of such treatment a dose of ketamine sufficient to alleviate symptoms associate... | 02/17/2011 |
| 20110027193 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of common cold, utilizing various method of administration of X-ray contrast med... | 02/03/2011 |
| 20100329999 | Antiperspirant Aerosol Composition According to a first aspect, antiperspirant aerosol compositions are disclosed comprising antiperspirant active particulates, a propellant and at least 5% by weight of the entire antiperspirant aerosol composition of a silicone component, wherein (a) the antiperspirant ... | 12/30/2010 |
| 20100329984 | RESPIRATORY DISPERSION FOR METERED DOSE INHALERS A respiratory dispersion for pulmonary delivery comprises one or more bioactive agents, a suspension medium, and a plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 μm. The suspension medium comprises at least one propellant and ... | 12/30/2010 |
| 20100330186 | MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC A pharmaceutical composition comprising a compound of formula 1 wherein X− is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable exc... | 12/30/2010 |
| 20100285142 | Method Of Making Particles For Use In A Pharmaceutical Composition A method for making composite excipient particles for use in a pharmaceutical composition comprises a milling step in which particles of an excipient material are milled in the presence of an additive material. The product particles are of small size and the milling req... | 11/11/2010 |
| 20100284940 | METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO ENABLE RAPID RELIEF OF MIGRAINE WHILE MINIMIZING SIDE EFFECT PROFILE Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising... | 11/11/2010 |
| 20100247452 | USE OF ERYTHROPOIETIN The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of end... | 09/30/2010 |
| 20100247450 | USE OF ERYTHROPOIETIN The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of end... | 09/30/2010 |
| 20100247451 | USE OF ERYTHROPOIETIN The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of end... | 09/30/2010 |
| 20100215707 | ACTIVATED CREATININE AND PRECURSORS THEREOF AS ANTIBACTERIAL AGENTS, COMPOSITIONS AND PRODUCTS CONTAINING SUCH AGENTS AND USES THEREOF Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, composi... | 08/26/2010 |
| 20100215590 | Micronization Method The invention relates to a method for producing a micronized, virtually anhydrous form of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide, said form per se, and the use thereof for produci... | 08/26/2010 |
| 20100143269 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ASTHMA Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and formoterol fumarate and processes for preparing the same.... | 06/10/2010 |
| 20100143268 | Formulations for Delivery Via Pressurised Metered Dose Inhalers Comprising an Essential Oil as Suspension Stabiliser A formulation suitable for delivery from a pressurised metered dose inhaler comprises a hydrofluoroalkane liquid, which is pharmaceutically acceptable, for instance HFA 134a or HFA 227, a drug to be delivered to the lung which is insoluble in the hydrofluoroalkane, the ... | 06/10/2010 |
| 20100124536 | Hemophilia Treatment by Inhalation of Coagulation Factors Hemophilia treatment by the inhalation of coagulation factors. Dry powder Factor IX is aerosolized to a mass median aerodynamic diameter of 4 μm or less, with at least 90% monomer content, at least 80% activity level, and 10% water or less. The aerosol is slowly, and d... | 05/20/2010 |
| 20100095963 | PHARMACEUTICAL COMPOSITIONS Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and processes for preparing the same.... | 04/22/2010 |
| 20100055192 | MICRONIZED PARTICLES OF LOW-DOSAGE STRENGTH ACTIVE AGENTS FOR POWDER FORMULATIONS FOR INHALATION Micronized particles of a low-dosage strength active ingredient, to be used in dry powder formulations for inhalation, with particular properties can easily and homogenously disperse in a dry powder formulation to be administered by means of a dry powder inhaler device.... | 03/04/2010 |
| 20100055049 | INSULIN DERIVATIVE FORMULATIONS FOR PULMONARY DELIVERY Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.... | 03/04/2010 |
| 20100047292 | METHODS OF PROCESSING MICROPARTICLES AND COMPOSITIONS PRODUCED THEREBY A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion including dispersed and continuous phases, positioning the multi-phasic dispersion within a chamber capable of being pressurized, pressurizing the cham... | 02/25/2010 |
| 20100028269 | DRY POWDER FORMULATIONS A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is c... | 02/04/2010 |
| 20100015217 | Enhancing Pulmonary Host Defense via Administration of Granulocyte-Macrophage Colony Stimulating Factor The present invention provides methods for enhancing pulmonary host defense in a subject by administering via inhalation an effective amount of granulocyte-macrophage colony stimulating factor or a functional homologue thereof. Methods of the present invention are usefu... | 01/21/2010 |
| 20090324512 | POLYPEPTIDE CONSTRUCTS FOR NASAL ADMINISTRATION The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from C... | 12/31/2009 |
| 20090291050 | PARTICULATE MATERIALS Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing the particles or formulations. In one embodiment, an inhaler contains an aerosol formu... | 11/26/2009 |
| 20090260271 | Visible animal scent and dispersion system An animal scent composition contains animal generated scents and a visual indicator to allow visualization of scent travel and application. The scent may be used for repelling wild and domestic animals, for attracting game animals, and for masking the scent of humans. D... | 10/22/2009 |
| 20090258040 | STEROID TREATMENT FOR HOT FLASHES Embodiments of the invention relate to methods for treating individuals suffering from hot flashes by vomeronasally administering a therapeutically effective dosage of a steroid agent. The hot flashes may be a result of postmenopause or castration suffered by the indivi... | 10/15/2009 |
| 20090238772 | METHODS AND COMPOSITIONS FOR PREVENTION OR TREATMENT OF RSV INFECTION Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical admi... | 09/24/2009 |
| 20090220581 | METHODS OF REDUCING INFLAMMATION AND MUCUS HYPERSECRETION Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protei... | 09/03/2009 |
| 20090110647 | METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1 A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises ... | 04/30/2009 |
| 20090104127 | SUSPENSION AEROSOL FORMULATIONS OF PHARMACEUTICAL PRODUCTS Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.... | 04/23/2009 |
| 20090098209 | PHARMACEUTICAL COMPOSITIONS CONTAINING WATER-SOLUBLE DERIVATIVES OF PROPOFOL AND METHODS OF ADMINISTERING SAME VIA PULMONARY ADMINISTRATION The present invention is directed to methods of delivering propofol derivative compounds via pulmonary administration to a mammal in order to induce or maintain anesthetized, sedated and sub-hypnotic states.... | 04/16/2009 |
| 20090081302 | PULMONARY DELIVERY OF POLYENE ANTIFUNGAL AGENTS The present invention provides spray-dried polyene compositions for oral inhalation to the lung. The polyene antifungal compositions demonstrate superior aerosol properties, do not exhibit appreciable degradation of the polyene upon spray-drying, and are useful in the t... | 03/26/2009 |
| 20090041682 | MEDICAL PRODUCT The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ... | 02/12/2009 |
